Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors

Stock News09-22

Jiangsu Yahong Meditech Co., Ltd. (688176.SH) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced solid tumors. This milestone marks a key step forward for the company's oncology pipeline.

The APL-2501 molecule, known chemically as BLB101, is an antibody-drug conjugate (ADC) designed around a proprietary hydrophilic linker and a topoisomerase inhibitor payload. It specifically targets CLDN6/9 antigens, which are expressed across multiple tumor types.

According to the company's statement, APL-2501 holds broad therapeutic potential. It is intended to treat a range of advanced solid tumors, including ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer, among others.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109466006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109466006","market":"sg","top_or_hot":-1,"title":"Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors","media":"Stock News","content":"<p><b>Jiangsu Yahong Meditech Co., Ltd.</b> (<b>688176.SH</b>) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced solid tumors. This milestone marks a key step forward for the company's oncology pipeline.<br><br>The APL-2501 molecule, known chemically as BLB101, is an antibody-drug conjugate (ADC) designed around a proprietary hydrophilic linker and a topoisomerase inhibitor payload. It specifically targets CLDN6/9 antigens, which are expressed across multiple tumor types.<br><br>According to the company's statement, APL-2501 holds broad therapeutic potential. It is intended to treat a range of advanced solid tumors, including ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer, among others.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-22 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Jiangsu Yahong Meditech Co., Ltd.</b> (<b>688176.SH</b>) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced solid tumors. This milestone marks a key step forward for the company's oncology pipeline.<br><br>The APL-2501 molecule, known chemically as BLB101, is an antibody-drug conjugate (ADC) designed around a proprietary hydrophilic linker and a topoisomerase inhibitor payload. It specifically targets CLDN6/9 antigens, which are expressed across multiple tumor types.<br><br>According to the company's statement, APL-2501 holds broad therapeutic potential. It is intended to treat a range of advanced solid tumors, including ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer, among others.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1109466006","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109466006","pubTimestamp":1790070404,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Yahong Meditech Co., Ltd. (688176.SH) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688176":"亚虹医药-U","BK1574":"生物医药B类股","09939":"开拓药业-B","MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0239":"医药制造","BK1515":"抗疫概念","BMED":"iShares Health Innovation Active ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK1161":"生物科技"},"translate_title":"亚宏医疗APL-2501在晚期实体瘤I期研究中为首例患者注射","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688176":1,"IBBQ":1,"IBBJ":1,"BMED":1,"PSYK":1,"09939":1,"MDTX":1},"content_text":"Jiangsu Yahong Meditech Co., Ltd. (688176.SH) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced solid tumors. This milestone marks a key step forward for the company's oncology pipeline.The APL-2501 molecule, known chemically as BLB101, is an antibody-drug conjugate (ADC) designed around a proprietary hydrophilic linker and a topoisomerase inhibitor payload. It specifically targets CLDN6/9 antigens, which are expressed across multiple tumor types.According to the company's statement, APL-2501 holds broad therapeutic potential. It is intended to treat a range of advanced solid tumors, including ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer, among others.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109466006","isCrawlerRequest":true}